Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROMIST vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute coronary syndrome (off-label),Heart failure with preserved ejection fraction (off-label),Anal fissure (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Primarily hepatic via glutathione S-transferases (GST) and possibly cytochrome P450 (CYP3A4) to inactive metabolites.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound to plasma proteins (albumin).
Isosorbide mononitrate is less than 5% bound to plasma proteins.
3.3 L/kg; large Vd indicates extensive tissue distribution, especially to vascular smooth muscle.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: ~40% (due to first-pass metabolism); transdermal: variable (~10–30%); intravenous: 100%.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required for renal impairment.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction due to increased bioavailability.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Initiate with lower doses (e.g., 1 spray = 0.4 mg) due to increased sensitivity and higher risk of hypotension.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
None.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension,Hypovolemia,Increased intracranial pressure,Hypertrophic cardiomyopathy,Severe anemia,Tolerance with continuous use,Contraindicated use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin,Severe hypotension (SBP <90 mm Hg),Cardiac tamponade,Constrictive pericarditis,Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil),Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Severe anemia
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol consumption as it may enhance the hypotensive effects of nitroglycerin. No specific food restrictions, but a high-fat meal may delay absorption if taken orally; however, Nitromist is a sublingual spray, so food interactions are minimal.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: Increased risk of maternal hypotension leading to decreased placental perfusion. Not recommended.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio is approximately 0.55. American Academy of Pediatrics considers it compatible with breastfeeding. However, use caution in nursing mothers due to potential for infant hypotension.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
Standard dosing may be used but with caution due to increased plasma volume in pregnancy potentially altering pharmacokinetics. No specific dose adjustments recommended; start at lowest effective dose and titrate based on maternal response and fetal status.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Nitromist (nitroglycerin lingual spray) is indicated for acute relief of angina pectoris. Onset of action is 1-3 minutes. Administer 1-2 sprays onto or under the tongue at the first sign of an attack; may repeat every 5 minutes up to 3 doses in 15 minutes. Do not shake canister. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Hypotension, reflex tachycardia, and headache are common. Tolerance may develop with frequent use; a nitrate-free interval of 10-12 hours can minimize tolerance.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Use one or two sprays under or on the tongue at the first sign of chest pain; do not swallow. If no relief after 5 minutes, call 911.,Store at room temperature; do not expose to heat or open flame.,Do not shake the canister before use.,Sit down when using this medication to avoid dizziness or fainting.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra) while using this medication.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROMIST vs MONOKET, answered by our medical review team.
NITROMIST is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing c GMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROMIST and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROMIST is: 1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROMIST and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROMIST is classified as Category C. FDA Pregnancy Category X. Nitroglycerin is contraindicated in pregnancy due to risk of fetal bradycardia and hypotension. First trimester: Risk cannot be ruled out; use only if cle. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.